Test Price
2,800 AEDโ Home Collection Available
DCC Gene Mirror Movements Type 1 NGS Genetic Test in Dubai, UAE โ 2,800 AED
Executive Summary & Core Metrics
Executive Summary
The DCC Gene Mirror Movements Type 1 Genetic Test is a high-precision diagnostic assay employing Next-Generation Sequencing (NGS) to detect pathogenic variants in the DCC gene causative of congenital mirror movements disorder. Priced at 2,800 AED with a turnaround time of 3 to 4 weeks, the test achieves a diagnostic sensitivity of 99.9% under ISO 9001:2015 quality standards. Acceptable sample types include whole blood, extracted DNA, or dried blood spot on an FTA card. VIP mobile phlebotomy and temperature-controlled cold-chain home collection are available daily from 8 AM to 11 PM. Results include a telephonic clinical guidance session and direct insurance billing verification via WhatsApp.
Test Overview & Methodology
The DCC Gene Mirror Movements Type 1 NGS Test analyzes the DCC (Deleted in Colorectal Carcinoma) gene via Next-Generation Sequencing to identify pathogenic variants causative of congenital mirror movements disorder โ a rare neurological condition where voluntary movements of one limb are involuntarily mirrored by the contralateral limb. This test is clinically indicated for patients presenting with persistent, symmetric mirror movements since early childhood, aiding neurologists and medical geneticists in confirming diagnosis, guiding prognosis, and informing familial risk assessment.
| Parameter | Our Test โ DCC NGS | Closest Alternative โ Sanger Sequencing |
|---|---|---|
| Technology | Next-Generation Sequencing (NGS) | Sanger Sequencing (Single-Gene) |
| Diagnostic Sensitivity | 99.9% โ Full gene coverage including deep intronic regions | ~95% โ Exonic regions only; limited intronic coverage |
| Turnaround Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Variant Detection | SNVs, Indels, CNVs, Splice-Site Variants | SNVs and Small Indels Only |
| Regulatory Compliance | ISO 9001:2015 | DHA Licensed | UAE PDPL Compliant | Variable; May Lack UAE-Specific Accreditation |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh โ Consultant Medical Genetics, DHA Registration ID: 9294403
As a consultant medical geneticist with extensive experience in hereditary neurological disorders, I emphasize that the DCC NGS test is a powerful confirmatory tool that must be interpreted within the complete clinical and familial context. A positive result confirms the molecular diagnosis and facilitates accurate genetic counseling for autosomal dominant inheritance and recurrence risk. A negative result does not exclude other genetic or acquired etiologies of mirror movements. Every patient should review their results with their treating neurologist or genetic counselor before making any clinical decisions.
Clinical Advisory
Medication Advisory
Do not discontinue, adjust, or initiate any prescribed medication based solely on the results of this genetic test. Management of mirror movements and any associated neurological symptoms must remain under the direct supervision of your treating neurologist. Genetic test findings do not constitute a standalone treatment directive.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection
- Inability to provide adequate specimen volume (minimum 2 mL whole blood in EDTA tube)
- Severe anemia (Hb < 7 g/dL) contraindicating venipuncture โ consult managing physician
- For minors under 18 years: Absence of documented parental or legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability
- Active systemic infection with hemodynamic instability โ defer collection until clinically stable
- Known coagulopathy (INR > 2.0, Platelets < 50,000/ยตL) without prior medical clearance
Emergency Red Flags โ Seek Immediate Medical Attention
- Sudden onset or rapid progression of new movement abnormalities
- Development of unexplained seizures or loss of consciousness
- Acute-onset limb weakness, facial droop, or speech difficulty (possible stroke)
- Severe headache with nausea, vomiting, or visual disturbances
- Any signs of increased intracranial pressure โ do not delay emergency evaluation
Patient FAQ & Clinical Guidance
1. What is the DCC Gene Mirror Movements Type 1 NGS Test, and why is it performed?
The DCC NGS test sequences the entire coding region of the DCC gene to identify pathogenic mutations causing congenital mirror movements disorder, a rare neurological condition evident from early childhood. This test is clinically indicated when a patient presents with persistent, bilateral, symmetric involuntary mirroring of voluntary limb movements โ for example, when moving the right hand, the left hand involuntarily replicates the same action. Confirming a DCC pathogenic variant through NGS provides definitive molecular diagnosis, eliminates diagnostic uncertainty, and enables precise genetic counseling regarding autosomal dominant inheritance patterns and recurrence risks for future pregnancies. The test requires a blood sample, extracted DNA, or a dried blood spot on an FTA card, with results available in 3 to 4 weeks.
2. How is the sample collected, and what is the turnaround time for results?
Sample collection is performed via a standard venipuncture drawing 2โ3 mL of whole blood into an EDTA tube, or alternatively by providing extracted DNA or a single drop of blood on an FTA card. Our VIP mobile phlebotomy and temperature-controlled cold-chain home collection service operates across all UAE Emirates from 8 AM to 11 PM, deploying ISO-certified logistics to preserve specimen integrity from the point of collection to our DHA-licensed laboratory facility. Once the sample is accessioned, Next-Generation Sequencing analysis requires 3 to 4 weeks for completion, including library preparation, sequencing on high-fidelity platforms, bioinformatics alignment against the reference genome, and variant interpretation by board-certified clinical molecular geneticists. Patients receive a comprehensive report detailing any identified variants, their clinical significance per ACMG classification, and recommendations for follow-up genetic counseling.
3. Do I need a doctor's referral to take this test in the UAE?
A valid referral from a DHA-licensed neurologist or medical geneticist is strongly recommended to ensure appropriate clinical indication, pre-test genetic counseling, and accurate post-test result interpretation. While individuals may self-request genetic testing under UAE regulations, Federal Decree-Law No. 45 of 2021 on Personal Data Protection and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields mandate that all genetic testing facilities verify the clinical appropriateness of the test and ensure informed consent is documented prior to sample processing. For minors, Federal Decree-Law No. 4 of 2016 on Medical Liability requires explicit parental or legal guardian consent. Our facility provides a mandatory pre-test genetic counseling session to review the patient's clinical history, construct a pedigree chart of affected family members, and explain the implications of potential test results โ including the possibility of variants of uncertain significance (VUS). Post-test, a telephonic clinical guidance session with our consulting medical geneticist is included at no additional charge to help contextualize findings within the patient's overall neurological health.
UAE Regulatory & Data Privacy Adherence
Legal Frameworks
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability
- DHA Facility License No: 1143
Quality Certifications
- ISO 9001:2015 โ Certificate No: INT/EGQ/2509DA/3139
- Next-Generation Sequencing (NGS) on Validated Platforms
- ACMG/AMP Variant Interpretation Standards
- DHA-Certified Clinical Geneticists on Review Panel
Clinical & Logistical Metadata
| Test Name | DCC Gene Mirror Movements Type 1 NGS Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA Card โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G11.8 |
| LOINC Code | 101135-2 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians